Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 601 - 625 of 14526 in total
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain,...
Approved
Matched Description: … soft tissue pain, and ankylosing spondylitis. ... tablet, injectable, nasal spray and as an ophthalmic solution. ... Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral …
Matched Categories: … Mydriatics and Cycloplegics ... phenylephrine and ketorolac ... Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site. It plays an essential role as an antioxidant in neutralizing food...
Approved
Matched Description: … foods from animal and plant products. ... Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in ... It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe pain, progressive multi-organ damage, and premature death. Treatment options for SCD are largely focused on preventing the production and circulation of...
Approved
Investigational
Matched Description: … [A262691] Treatment options for SCD are largely focused on preventing the production and circulation ... ] - a mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor ... [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease …
Matched Categories: … Blood and Blood Forming Organs …
Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Description: … A biguanide hypoglycemic agent with actions and uses similar to those of metformin. …
Matched Categories: … Alimentary Tract and Metabolism ... phenformin and sulfonylureas …
Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as...
Approved
Investigational
Matched Description: … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment ... non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ... It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … neutralizes several RSV A and B strains. ... antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and ... the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … It also tends to lower blood pressure and increase potassium loss. …
Matched Categories: … Genito Urinary System and Sex Hormones ... metolazone and potassium-sparing agents ... Gynecological Antiinfectives and Antiseptics ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Matched Description: … It is used in musculoskeletal and joint disorders and administered by mouth and topically. ... An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … and maintenance of hemostasis [A18581]. ... in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643] Glucagon was granted FDA...
Approved
Matched Description: … diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and ... Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic ... the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and
Matched Categories: … Alimentary Tract and Metabolism ... Belladonna and Derivatives, Plain ... butylscopolamine and analgesics …
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … the chronic complications such as chronic active hepatitis and cirrhosis. ... epidemiology vary widely among geographical areas and population subgroups. ... Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Bacterial and viral vaccines, combined ... haemophilus influenzae B and hepatitis B …
The respiratory protein of the red blood cells. It consists primarily of globin and heme.
Approved
Experimental
Investigational
Matched Description: … It consists primarily of globin and heme. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for ... porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and
Matched Categories: … Blood and Blood Forming Organs …
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000...
Approved
Withdrawn
Matched Description: … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. ... Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored …
Matched Categories: … Enzymes and Coenzymes …
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Matched Categories: … sotalol and thiazides ... Beta Blocking Agents and Thiazides ... sotalol and acetylsalicylic acid ... Beta Blocking Agents, Non-Selective, and Thiazides …
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … increase the number and sensitivity of insulin receptors. ... Renal and hepatic dysfunction may increase the risk of hypoglycemia. ... Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Displaying drugs 601 - 625 of 14526 in total